We look forward to sharing additional Phase 1/2 data next week at the Muscular Dystrophy Association's annual meeting and ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果